ADVAIR DISKUS 100/50 Drug Patent Profile

When do Advair Diskus 100/50 patents expire, and when can generic versions of Advair Diskus 100/50 launch?

Advair Diskus 100/50 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ADVAIR DISKUS 100/50 is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advair Diskus 100/50

A generic version of ADVAIR DISKUS 100/50 was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for ADVAIR DISKUS 100/50

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	59
DailyMed Link:	ADVAIR DISKUS 100/50 at DailyMed

Recent Clinical Trials for ADVAIR DISKUS 100/50

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Becro Ltd.	Phase 3
Teva Pharmaceuticals USA	Phase 3
Respirent Pharmaceuticals Co Ltd.	Phase 1

See all ADVAIR DISKUS 100/50 clinical trials

Pharmacology for ADVAIR DISKUS 100/50

Drug Class	Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ADVAIR DISKUS 100/50

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ADVAIR DISKUS 100/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-001	Aug 24, 2000	AB	RX	Yes	Yes

Expired US Patents for ADVAIR DISKUS 100/50

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	ADVAIR DISKUS 100/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-001	Aug 24, 2000

EU/EMA Drug Approvals for ADVAIR DISKUS 100/50

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Airexar Spiromax	salmeterol xinafoate, fluticasone propionate	EMEA/H/C/004267Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1	Withdrawn	no	no	no	2016-08-18

International Patents for ADVAIR DISKUS 100/50

See the table below for patents covering ADVAIR DISKUS 100/50 around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	395427
Austria	395428
Austria	395429
Austria	401521
Austria	A17084
Austria	A203186

Supplementary Protection Certificates for ADVAIR DISKUS 100/50

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0416951	C990012	Netherlands		PRODUCT NAME: SALMETEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN FLUTICASONPROPIONAAT,IN HET BIJZONDER SALMETEROLXINAFOAAT EN FLUTICASONPROPIONAAT; NATL REGISTRATION NO/DATE: RVG 23529 - RVG 23534 19990112; FIRST REGISTRATION: SE 14591 - 14596 19980907
0416951	12/1999	Austria		PRODUCT NAME: SALMETEROL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH DES 1-HYDROXY-2-NAPHTHOATS (XINAFOAT) UND FLUTICASON PROPIONAT; NAT. REGISTRATION NO/DATE: 1-22897,1-22898, 1-22899,1-22900, 1-22901,1-22902 19990204; FIRST REGISTRATION: SE 14591-14596 19980907
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215

Last updated: July 30, 2026

ADVAIR DISKUS 100/50 Market Dynamics and Financial Trajectory (Fluticasone Propionate/Salmeterol)

Executive summary: ADVAIR DISKUS 100/50 (fluticasone propionate 100 mcg plus salmeterol 50 mcg) remains a mature, high-volume branded inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) franchise facing steady substitution from generic fluticasone/salmeterol products and other respiratory therapies. Financial trajectory is dominated by (1) US patent and exclusivity expirations that enabled broad generic entry, (2) persistent competitive pricing pressure in inhaled respiratory classes, and (3) channel demand patterns driven by payer policy and formulary placement. This product’s market is now largely “maintenance” revenue rather than growth, with volume shifting to lower-cost equivalents and to alternative asthma/COPD controller regimens.

---

When did ADVAIR DISKUS 100/50 lose brand exclusivity and how did that change pricing?

Featured snippet answer: ADVAIR DISKUS brand exclusivity has already ended; generic fluticasone/salmeterol products entered the market and reset the pricing baseline for the combination.

Exclusivity and generic entry timeline (US)

• ADVAIR DISKUS is a fluticasone propionate/salmeterol inhalation powder combination indicated for:
  • asthma (in patients not adequately controlled on a similar controller regimen), and
  • COPD (in patients with adequate clinical indications based on labeling history and regulatory evolution).
• The combination’s brand period ended years ago via patent expirations and/or exclusivity milestones, followed by widespread generic availability.
• Post-generic period pricing typically follows a stair-step pattern: initial discounting to preserve share, then further compression as multiple ANDA filers launch and gain pharmacy channel uptake.

What this meant for market dynamics

• Formulary re-basing: Payers shifted to preferred generic fluticasone/salmeterol and set narrow criteria for brand.
• Unit economics: Retail and PBM contracting moved to lowest-cost equivalent-based tiers, reducing the effective net price for branded DISKUS.
• Therapy substitution elasticity: Asthma controller patients often remain on the same molecule pair if it is therapeutically acceptable and covered, but cost-sharing drives “brand vs generic” switching.

---

What generic fluticasone/salmeterol products compete with ADVAIR DISKUS 100/50?

Featured snippet answer: The key competitive set is generic fluticasone/salmeterol inhalation powder in comparable strengths, plus class competitors in asthma and COPD controller space.

Direct combination competitors (same active ingredients)

• Generic fluticasone propionate/salmeterol inhalation powder products in strength-matched or near-matched dosage ratios (including 100/50 equivalents where available).
• Biosimilar constructs do not apply here because this is a small molecule combination, not a biologic.

Class competitors that can shift demand

• Other ICS/LABA controllers (non-DISKUS device lines or alternative inhalation powders/aerosols)
• ICS alone options for patients whose LABA use is reduced
• MART/SMART strategies and guideline-driven controller step therapy in asthma, which can influence which LABA-containing products are selected

Device and adherence impact

• DISKUS is a dry powder inhaler; adherence varies by patient technique and inhalation flow coordination. Substitution to other inhalation devices can happen when coverage improves or when device education and clinical inertia align.

---

How does ADVAIR DISKUS 100/50 compare financially with newer ICS/LABA controllers?

Featured snippet answer: ADVAIR DISKUS faces declining or flat growth prospects relative to newer inhaler launches and branded reformulations, because generic competition erodes branded net pricing and share.

Competitive positioning

• ADVAIR DISKUS is a legacy franchise in a category where:
  • payers prefer lower-cost equivalents once available,
  • patient and prescriber behavior tends to stabilize on covered products,
  • inhaler innovations matter for switching, but coverage often dominates.

Implications for revenue trajectory

• After generic entry, the branded product’s revenue typically becomes:
  • more dependent on inertia, higher-acuity prescriber patterns, and remaining “brand-only” formulary exceptions,
  • less dependent on new patient starts.
• Newer branded ICS/LABA competitors tend to capture incremental patient starts through contracting, co-pay support (where permitted), and broader formulary access early in their lifecycle.

---

What is the Orange Book status of ADVAIR DISKUS 100/50 and what patents drive generic entry risk?

Featured snippet answer: ADVAIR DISKUS’s combination is not protected by active, brand-blocking exclusivity against generics in routine commercial use; the product faces ongoing generic competition because historical barriers have expired.

Orange Book driven risk structure (how it typically works for combinations like this)

• Combination products usually have:
  • drug substance and drug product composition patents,
  • method-of-manufacture or formulation particle engineering patents,
  • device-related patents (if applicable) tied to inhaler performance and dose consistency.
• Once these expire, ANDA approvals can proceed without further Paragraph IV litigation in the absence of new, later-expiring patents.

Commercial effect

• The business outcome is a mature branded asset with:
  • limited long-term upside,
  • predictable revenue compression,
  • market share capped by net pricing and coverage.

---

What patent litigation history affects ADVAIR DISKUS 100/50 settlement dynamics and launch timing?

Featured snippet answer: ADVAIR DISKUS entered a post-litigation, post-generic environment where remaining risk is usually limited to residual patents or reformulation/device-specific claims rather than core molecule protections.

How litigation impacts market dynamics

• In respiratory inhalers, Paragraph IV challenges often target:
  • formulation stability,
  • particle size distribution and consistent dosing,
  • manufacturing processes and specifications.
• Settlements can delay generic launches, but once the bulk of the estate expires, subsequent waves of generics can launch with reduced friction.

Business impact now

• Current competitive pricing reflects the cumulative effect of multiple generic and distributor cycles rather than active restriction.

---

What formulations and strengths are most substitutable for ADVAIR DISKUS 100/50?

Featured snippet answer: Strength-matched fluticasone/salmeterol products and equivalent controller strategies are the most direct substitutes.

Strength substitution logic

• Clinicians match ICS dose intensity and LABA dosing to severity. If the 100/50 strength is not covered, prescribers may:
  • switch to a covered strength ratio,
  • step down or step up within guideline ranges,
  • change inhaler device based on coverage and technique.

Device substitutability

• Switching from DISKUS to another inhaler device type is plausible, especially when insurance policy changes.

---

How do payer policies shape ADVAIR DISKUS 100/50 demand?

Featured snippet answer: Payer tier placement and copay design determine net revenue more than incremental clinical differentiation.

Key payer levers

• Formulary tiering: generics on preferred tiers; brand moved to non-preferred.
• Prior authorization: often requires step therapy history, inhaler technique documentation, or evidence of failure on lower-cost controllers.
• Quantity and step edits: can reduce brand persistence and increase generic switching.

Net revenue mechanics

• Even when prescriptions stay constant, net price declines through:
  • lower brand acquisition pricing,
  • higher discounts,
  • patient cost-sharing offsets (copay assistance is limited once a product is off-formulary or when payer restrictions apply).

---

What are the major manufacturing and supply-chain risks for ADVAIR DISKUS 100/50?

Featured snippet answer: Supply reliability is a key risk in inhalation powders; however, the competitive landscape is dominated by pricing and contracting rather than supply constraints.

Manufacturing considerations in dry powder inhalers

• Particle engineering consistency (for dose uniformity)
• Packaging and moisture control to preserve potency
• Device dose delivery consistency
• Line changes and regulatory comparability batches

Commercial takeaway

• Any supply disruption can temporarily improve share for a short window, but generic competition usually restores normal share once supply returns.

---

What generic entry risks exist for the ADVAIR DISKUS 100/50 brand today?

Featured snippet answer: The remaining brand entry risks are more about incremental generic waves and contracting than about new legal barriers.

Risk profile

• Additional generic filers can increase:
  • pharmacy substitution rates,
  • wholesaler promotional pricing pressure,
  • PBM “spread” outcomes that favor generics.
• Minor formulation variants may trigger new market entrants but do not typically create sustained price premiums for the brand once broad generic coverage exists.

---

How strong is the patent estate for the ADVAIR DISKUS 100/50 franchise and what does it mean for revenue durability?

Featured snippet answer: The franchise is no longer in a peak patent-protection phase; revenue durability relies on non-patent market factors: inertia, payer exceptions, and prescriber preference.

Estate strength in a practical commercial sense

• For mature ICS/LABA brands, the “strength” that matters commercially is:
  • whether meaningful barriers still block all AB-rated generics,
  • whether later-expiring patents still cover a protected device or formulation used by patients.
• Once generics are broadly available, legal strength translates into limited incremental protection unless the product is uniquely shielded by still-active, blocking patents.

---

Key timeline: what drives the financial trajectory of ADVAIR DISKUS 100/50 after genericization?

Period	Dominant driver	Expected financial impact
Pre-generic	brand exclusivity	highest net price, share growth from patient starts
Post-first generic launches	contracting and price compression	brand net price declines; share erosion begins
Multi-generic stabilization	tiering and widespread substitution	revenue flattens or declines steadily
Mature phase	payer step edits, switched patients, competitive class pressures	sustained decline or low single-digit churn in share
Late lifecycle	residual brand pockets	“maintenance” revenue, typically decreasing

---

Key Takeaways

• ADVAIR DISKUS 100/50 is in a mature, generic-competitive market where pricing pressure and formulary placement dominate revenue trajectory.
• Brand durability is constrained by the availability of lower-cost generic fluticasone/salmeterol equivalents and by therapy-management pathways in asthma and COPD.
• The product’s future financial path is most sensitive to payer contracting (tiering, prior authorization, quantity and step edits) rather than to incremental clinical differentiation.
• Patent and Orange Book barriers have largely translated into a post-exclusivity environment, shifting the business to managing shrinking branded net price, residual share, and substitution dynamics.

---

FAQs

1. How do prior authorizations typically affect ADVAIR DISKUS 100/50 brand prescriptions versus generics?
2. Does switching from ADVAIR DISKUS to another ICS/LABA reduce exacerbation risk enough to change formulary behavior?
3. What is the usual substitution pattern when a payer excludes DISKUS but covers an equivalent fluticasone/salmeterol strength in another inhaler device?
4. How do PBM rebate structures change branded net price after broad generic entry for fluticasone/salmeterol?
5. What market signals indicate whether branded ICS/LABA inhalers will lose more share to generics or gain from newer branded competitors?

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drug Trials Snapshots for approved products (search portal). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots